Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma
About this trial
This is an interventional treatment trial for Cervical Adenocarcinoma
Eligibility Criteria
Inclusion Criteria: Diagnosis of cervical cancer Any histology Documented or suspected central pelvic disease with or without pelvic sidewall fixation from tumor and/or radiation fibrosis Meets 1 of the following stage criteria: Recurrent disease, defined as reappearance of disease after a complete clinical response lasting ≥ 1 month Persistent disease, defined as presence of disease by biopsy ≥ 3 months after completion of primary therapy Must have received prior primary treatment, including any of the following: Surgery with or without post operative radiotherapy with or without chemotherapy Primary radiotherapy with or without chemotherapy Neoadjuvant chemotherapy followed by surgery Neoadjuvant chemotherapy followed by surgery with or without radiotherapy or chemotherapy Plans to undergo pelvic exenteration to remove the pelvic disease within 14 days after study entry Deemed to be a good surgical candidate No evidence of distant disease or disease that is felt to be unresectable by physical examination Patients with suspicious pelvic or para-aortic nodal disease as the only site(s) of extrapelvic disease are eligible at the discretion of the surgeon Patients whose surgery is planned solely for managing complications (e.g., rectovaginal fistula, vesicovaginal fistula) of disease or prior therapy are not eligible Patients whose surgery is planned as a prophylactic measure due to a slow or suboptimal clinical or radiographical tumor response during the course of primary therapy are not eligible No distant site of metastases by CT scan or MRI of the abdomen/pelvis OR positron-emission tomography No noncervical primary tumor No prior anterior or posterior pelvic exenteration
Sites / Locations
- University of Alabama at Birmingham Cancer Center
- Colorado Gynecologic Oncology Group
- Hartford Hospital
- The Hospital of Central Connecticut
- Beebe Medical Center
- Christiana Care Health System-Christiana Hospital
- Georgia Regents University Medical Center
- Memorial University Medical Center
- Indiana University/Melvin and Bren Simon Cancer Center
- Union Hospital of Cecil County
- University of Minnesota Medical Center-Fairview
- Washington University School of Medicine
- The Cancer Institute of New Jersey Hamilton
- Rutgers Cancer Institute of New Jersey
- Roswell Park Cancer Institute
- University of North Carolina at Chapel Hill
- Cleveland Clinic Cancer Center/Fairview Hospital
- Cleveland Clinic Foundation
- Ohio State University Comprehensive Cancer Center
- Hillcrest Hospital Cancer Center
- Lake University Ireland Cancer Center
- University of Oklahoma Health Sciences Center
- Cancer Care Associates-Midtown
- Tulsa Cancer Institute
- Gynecologic Oncology Group
- M D Anderson Cancer Center
- Auburn Regional Medical Center
- Providence Regional Cancer System-Centralia
- Saint Francis Hospital
- Saint Clare Hospital
- Providence - Saint Peter Hospital
- Capital Medical Center
- MultiCare Good Samaritan Hospital
- MultiCare Allenmore Hospital
- MultiCare Tacoma General Hospital
- Northwest CCOP
- Saint Joseph Medical Center
- Multicare Health System
- M D Anderson International Spain
Arms of the Study
Arm 1
Experimental
Treatment (pelvic exenteration)
Patients undergo pelvic exenteration within 14 days after study entry.